Each year, 500 to 1,000 people in the United States are diagnosed with pulmonary arterial hypertension (PAH). Because this progressive, chronic disorder is rare, it is often under-detected, causing ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Pulmonary arterial hypertension (PAH) is one of five types of pulmonary hypertension. It happens when the blood vessels in your lungs narrow and scar so much that it’s hard for blood to move ...

Supervised pulmonary rehabilitation exercises help severe PAH lung transplant candidates maintain or improve exercise ...

Two Indiana University doctors have been awarded grants by the American Lung Association Research Institute for their ...

Companies that manufacture diagnostics, technology and equipment to address the world’s most pressing medical issues have ...

The following is a summary of “Arterial stiffness measured by pulse wave velocity correlated with cognitive decline in ...

Opens in a new tab or window BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension ...

Chronic Pulmonary Hypertension Treatment Market. The global chronic pulmonary hypertension treatment market is expected to ...